



**DR GEOFF CUMMING DISCUSSES DIASOURCE ACQUISITION
FUNDING PACKAGE**

For Immediate Release:

December 1, 2015

1 December 2015 - Anteo Diagnostics (ASX: ADO) (**Anteo**), is pleased to invite investors to listen to an audio interview with CEO, Dr Geoff Cumming, where he discusses the proposed funding package for the acquisition of DIAsource Immunoassays SA, an established global specialty diagnostics company based in Belgium.

In this audiocast, Dr Cumming covers:

- Funding package in final stages consisting of a conditional Heads of Agreement for a Convertible Note of €10,000,000 and an Entitlement Issue (non-renounceable rights issue) of up to \$12,018,427.
- Rationale for proposed debt and equity funding package.
- Opportunity for shareholders to participate in the Entitlement Issue (1 new share for every 5.35 currently held shares) and option to oversubscribe.
- Entitlement Issue pricing: \$0.075 per ADO share, a 14.3% discount to VWAP and a 12.8% discount to ADO closing share price on 27 November 2015.
- Anteo Directors' intention to take up their full entitlements.
- Entitlement offer key dates: shareholder participation record date of 4 December, offer opens on 8 December 2015, closes on 16 December 2015.
- DIAsource acquisition including funding anticipated to be completed by end of December.

To listen to the audiocast, please copy the following link into your browser:
<http://www.brrmedia.com/event/140914>

For further information, see our website (www.anteodx.com) or contact the persons outlined below.

Company	Media and Investors
Dr. Geoff Cumming, Chief Executive Officer T: + 61 7 3219 0085	Sean Kennedy, PAC Partners E: skennedy@pacpartners.com.au T: + 61 414 185 797
Richard Martin, Chief Financial Officer T: + 61 7 3219 0085	Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au T: + 61 411 117 774

About Anteo Diagnostics

Anteo Diagnostics Limited (ASX: ADO) is a global technology company and parent company of the Australian biotechnology company Anteo Technologies, that develops and commercialises products for the life sciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.

The Anteo group owns a patented nanogluce technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper or with greater specificity and / or sensitivity than incumbent tests. This nanogluce technology, called Mix&Go for healthcare markets, is starting to gain traction within the Company's target markets due to its ability to revolutionise the way scientists and assay developers work. For more information, please visit www.anteodx.com

For personal use only